Dunad Therapeutics
Biopharmaceutical company that applies tunable covalent chemistry together with disease biology research to discover and develop targeted small-molecule therapeutics.
Industries
Biotechnology
Pharmaceutical
Biotechnology Research
Nr. of Employees
small (1-50)
Patents
Products
ALS (Amyotrophic Lateral Sclerosis) Program
A covalent, oral small-molecule therapy aimed at reducing toxic TDP43 protein buildup in the brain and spinal cord as a treatment for ALS.
ALS (Amyotrophic Lateral Sclerosis) Program
A covalent, oral small-molecule therapy aimed at reducing toxic TDP43 protein buildup in the brain and spinal cord as a treatment for ALS.
Expertise Areas
- Covalent chemistry-based drug discovery
- Target identification and validation using disease biology
- Small-molecule therapeutic design and development
Key Technologies
- Tunable covalent chemistry
- Targeted small-molecule design
- Disease biology research
- Medicinal chemistry